公开(公告)号：US20220183965A1

公开(公告)日：2022-06-16

申请号：US17574511

申请日：2022-01-12

Applicant: Impel Neuropharma, Inc.

Inventor： John D. Hoekman ,  Kelsey H. Satterly ,  Inna Dashevsky ,  Aditya R. Das

IPC: A61K9/00 ,  A61K31/5513 ,  A61M15/00 ,  A61K9/16 ,  A61P25/18 ,  A61K31/00

Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

公开(公告)号：US20150100042A1

公开(公告)日：2015-04-09

申请号：US14508701

申请日：2014-10-07

Applicant: Impel NeuroPharma Inc.

Inventor： John D. Hoekman ,  Asher Chao-Chi Chiu ,  Mei Xu

IPC: A61M25/00 ,  A61M25/06 ,  A61M31/00

CPC classification number: A61D7/00

Abstract: A muroid nasal device for intranasal delivery of compounds to the olfactory region.

Abstract translation: 一种用于将化合物鼻内递送至嗅觉区域的单克隆鼻腔装置。

公开(公告)号：US11278492B2

公开(公告)日：2022-03-22

申请号：US16240653

申请日：2019-01-04

Applicant: Impel Neuropharma, Inc.

Inventor： John D. Hoekman ,  Kelsey H. Satterly ,  Inna Dashevsky ,  Aditya R. Das

IPC: A61K9/00 ,  A61P25/18 ,  A61K31/5513 ,  A61M15/00 ,  A61K9/16 ,  A61K31/00

Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

公开(公告)号：US11191910B2

公开(公告)日：2021-12-07

申请号：US16695147

申请日：2019-11-25

Applicant: Impel Neuropharma, Inc.

Inventor： John D. Hoekman ,  Alan Brunelle ,  Craig Kohring ,  Christopher Fuller

IPC: A61H15/00 ,  A61M15/00 ,  A61M11/00 ,  A61M15/08 ,  A61M11/02

Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.

公开(公告)号：US10507295B2

公开(公告)日：2019-12-17

申请号：US15338097

申请日：2016-10-28

Applicant: Impel NeuroPharma Inc.

Inventor： John D. Hoekman ,  Michael Hite ,  Alan Brunelle ,  Joel Relethford ,  Rodney J. Y. Ho

IPC: A61M15/08 ,  A61M11/02

Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.

公开(公告)号：US09919117B2

公开(公告)日：2018-03-20

申请号：US14075126

申请日：2013-11-08

Applicant: Impel NeuroPharma Inc.

Inventor： John D. Hoekman ,  Michael Hite ,  Alan Brunelle ,  Joel Relethford

IPC: A61M15/08 ,  A61M15/00 ,  A61M16/12 ,  B05B7/08 ,  B05B1/14 ,  A61M16/20

CPC classification number: A61M15/08 ,  A61M15/0021 ,  A61M16/127 ,  A61M16/208 ,  A61M2202/064 ,  A61M2210/0612 ,  A61M2210/0618 ,  A61M2210/1067 ,  A61M2210/1475 ,  B05B1/14 ,  B05B7/08

Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.

公开(公告)号：US20220105030A1

公开(公告)日：2022-04-07

申请号：US17492136

申请日：2021-10-01

Applicant: Impel Neuropharma, Inc.

Inventor： John D. Hoekman ,  Kelsey H. Satterly ,  Stephen B. Shrewsbury ,  Scott Youmans ,  Christopher Fuller

IPC: A61K9/00 ,  A61M11/00 ,  A61M11/02 ,  A61M15/00 ,  A61P25/06 ,  A61K31/48 ,  A61K31/522 ,  A61K47/26 ,  A61M15/08

Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax(Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

公开(公告)号：US20180256836A1

公开(公告)日：2018-09-13

申请号：US15759447

申请日：2016-09-09

Applicant: Impel NeuroPharma, Inc.

Inventor： John D. Hoekman ,  Christopher Fuller ,  Craig Kohring

IPC: A61M15/08 ,  A61M15/00

CPC classification number: A61M15/08 ,  A61M11/02 ,  A61M15/009 ,  A61M2210/0618 ,  A61M2210/005

Abstract: A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.

公开(公告)号：US20180236190A1

公开(公告)日：2018-08-23

申请号：US15890266

申请日：2018-02-06

Applicant: IMPEL NEUROPHARMA, INC.

Inventor： John D. Hoekman ,  Michael Hite ,  Alan Brunelle ,  Joel Relethford

IPC: A61M15/08 ,  B05B7/08 ,  A61M15/00 ,  B05B1/14 ,  A61M16/12 ,  A61M16/20

CPC classification number: A61M15/08 ,  A61M15/0021 ,  A61M16/127 ,  A61M16/208 ,  A61M2202/064 ,  A61M2210/0612 ,  A61M2210/0618 ,  A61M2210/1067 ,  A61M2210/1475 ,  B05B1/14 ,  B05B7/08

Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.

公开(公告)号：US20160101245A1

公开(公告)日：2016-04-14

申请号：US14787455

申请日：2014-04-28

Applicant: IMPEL NEUROPHARMA INC.

Inventor： John D. Hoekman ,  Alan Brunelle ,  Craig Kohring ,  Christopher Fuller

IPC: A61M11/02 ,  B29C49/42 ,  B29C45/00 ,  B29C49/06 ,  A61M15/00 ,  A61M31/00

Abstract: A unit dose container for the containment of an intranasal formulation for use with the POD device.

Abstract translation: 用于容纳用于POD装置的鼻内制剂的单位剂量容器。